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Dear Sir,
Enhancement in MALDI-TOF MS analysis of the low molecular weight
human serum proteome
The combination in advances in MALDI-TOF MS instrumentation[1] and
serum sample preparation techniques[2 – 4] has led to the emergence of
MALDI serum protein expression profiling as a promising tool for biomarker
discovery.[5] However, three factors still pose significant challenges for
MALDI profiling of serum: the limited mass window of MALDI, serum
protein complexity[6] and analytical reproducibility.[7,8] MALDI has a small
mass preference due to the ionization efficiency of intact protein molecules
and the focusing of flight of ions towards the detector. In the linear mode,
TOF analyzers have limited sensitivity for masses above 20 kDa. To address
this, we previously reported the enhancement of MALDI broad mass
range detection of protein signals.[9] Spanning a 100-kDa mass range, we
improved the sensitivity of detection by an order of magnitude through
the combined optimization of sample preparation, instrument parameters
and data processing procedures.
The complexity of the blood proteome is very high, with protein
concentrations differing by up to ten orders of magnitude.[10] This large
dynamic range exceeds current proteomic analytical capabilities; thus,
analysis of easily prepared subproteomes of serum or plasma is essential.
Here, we shift our focus back to the enhancement of MALDI analysis in the
low mass regime. The low molecular weight (LMW) subcomponent of serum
promises to be a rich source of undiscovered biomarkers, as biological
processes give rise to a plethora of proteolytic protein fragments.[11]
Currently, there is no consensus on what constitutes the mass limits of
this derivative proteome (also termed peptidome). However, ‘<15 kDa’ is
often cited in the literature based on a serum MALDI study using 20 MWCO
filters.[12]
To date, small native protein/peptide mass measurements have been
mainly conducted in reflectron mode (<4 kDa)[13] and linear mode up to
10 kDa.[14] However, no systematic comparison has been described for a
combination of preparation steps: spotting, filtering and matrix choice, to
optimize the performance. A rigorous reproducibility study for different
preparation strategies is likewise missing, which prevents the extension of
the technique to clinical proteomics applications. The purpose of this work
was to provide such a systematic comparison, using rigorous performance
metrics to optimize sample preparation for LMW serum proteome profiling
by MALDI-TOF MS analysis up to 20 kDa. We explored a combination
of MALDI sample preparation and spotting methods. Procedures that
gave the best results included: (1) MALDI spotting with a thin-layer (TL)
technique using sinapinic acid on a ground steel plate and (2) centrifugal
ultrafiltration with 50 000 MWCO filters in the presence of 2% TFA, followed
by desalting with C3 magnetic beads. Ultrafiltration has been utilized
previously to improve MALDI profiling of serum.[2,13,15 – 17] However, our
approach extensively improves MALDI peak intensities of higher MW
peptides and small proteins, thus increasing biomarker coverage in the
3–20 kDa range. Reproducibility studies of a protein standard and serum
samples gave excellent results, all of which suggest that this procedure
can be a useful tool for proteome profiling of the LMW fraction of serum.
Experimental Procedures
All chemicals and solvents were purchased from Sigma–Aldrich (St. Louis,
MO, USA) unless otherwise noted. Protein standard 1 (PS1), MALDI matrices
and targets and ClinProt MB-C3 magnetic beads (C3) were obtained
from Bruker Daltonics (Leipzig, Germany). Amicon-4 and Amicon-0.5 Ultra
centrifugal filter devices were obtained from Millipore (Billerica, MA, USA).
A quality control (QC) serum sample was prepared by pooling human
serum from a controlled normal group as previously described.[18] Six
different MALDI target preparations and 23 different serum fractionations
were prepared to compare MALDI profiling in the LMW range (3–20 kDa).
Details are given in the following section.
Mass spectra were acquired in linear and reflectron positive ion
mode using an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker
Daltonics). The instrument is equipped with a smartbeam laser, and
acquisition laser power was optimized using the PS1 calibration mixture
before the collection of sample data. Instrument settings, optimized for
mass range m/z 0–20 000, were as follows: ion source 1 = 25.0 kV, ion
source 2 = 23.7 kV, lens voltage = 6.0 kV, pulsed ion extraction time
= 200 ns, matrix suppression mass cut off = 1500, ADC offset = 50,
pre-amplifier filter bandwidth = high, digitizer sampling frequency =
500 MHz. All spectra were generated by averaging 1000 shots from 10
nonoverlapping positions (100 shots/position).
Results and Discussion
MALDI spotting
Clinical profiling of body fluids by MALDI-MS is highly influenced by the
choice of MALDI spotting and sample preparation techniques. Our goal
was to determine an optimal method for MALDI profiling of LMW serum
protein/peptide ions, based on analytical performance measurements of
resolution, sensitivity, reproducibility and broad mass range coverage.
For sample/matrix crystal preparation, α-cyano-4-hydroxycinnamic acid
(CHCA) and sinapinic acid (SA) are most commonly used. Resolution
and sensitivity comparisons of these two matrices are well documented
in the literature; however, reproducibility studies are limited. Because
reproducibility is one of the most critical elements in profiling studies,
our main focus was to optimize reproducibility over the LMW serum
mass range (<20 kDa), without undermining other performance factors.
We evaluated a variety of matrices, sample/matrix ratios, ionic liquid
additives, target plates and spotting methods. We narrowed down the
principal comparisons to CHCA versus SA matrix (with no additives); Bruker
AnchorChip (600 µm) versus ground steel targets and dried droplet versus
TL spotting methods. The following six MALDI spotting methods were
compared in detail (target –matrix –spotting technique):
Anchorchip–CHCA–dried droplet.
Anchorchip–SA–dried droplet.
Steel–CHCA–dried droplet.
Steel–SA–dried droplet.
Steel–CHCA–thin layer.
Steel–SA–thin layer.
For the dried droplet (DD) method, matrices were dissolved in 50% ACN,
0.1% TFA, (5 mg/ml CHCA or saturated SA). Samples were mixed with
matrix in the ratio of 1 : 5, then 1 µl was spotted onto an AnchorChip or
ground steel plate. For our modified TL method, 0.3 µl of matrix solution
(CHCA saturated in MeOH or SA saturated in EtOH) was deposited onto the
ground steel target as a seed layer. Protein sample is mixed with matrix
solution as above, followed by 1 µl deposited onto the seed layer.
PS1 contains a good spread of ion signals in the range of 3–20 kDa
and was used to compare the different MALDI spotting methods. The
PS1 mixture contains insulin (5734 Da), ubiquitin (8565 Da), cytochrome
c (12 361 Da) and myoglobin (16 952 Da). PS1 was spotted ten times
for each preparation. A quick visual inspection showed the TL method
to be far superior to the more common DD method in the 3–20 kDa
range. An advantage of the TL method is the very homogeneous size
of microcrystals.[19] On deposition of the seed layer, the solution quickly
∗ Correspondence to: Christine L. Gatlin, National Human Genome Research
Institute/National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892,
USA. E-mail: christine.gatlin@nih.gov
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Figure 1. Averaged raw MALDI-TOF spectra (offset for clarity) of PS1
standard prepared by different spotting methods: (top) SA thin layer
on steel (ten replicates), (middle) CHCA thin layer on steel (ten replicates)
and (bottom) CHCA dried droplet on AnchorChip (nine replicates).
spreads and evaporates almost instantaneously (<2 s) leaving an ultra-thin
uniform coating. The method generally yields higher resolution spectra,
and the detection limit is increased compared with the DD method.
Of the six preparations, three were then statistically compared:
CHCA–DD on AnchorChip, CHCA–TL on steel plate and SA–TL on steel
plate. Signal processing was performed on raw PS1 spectra to enhance
signal to noise (SNR). Processing algorithms, described by Malyarenko
et al.[20] included analytical model baseline subtraction, integrative down-
sampling optimal linear filtering, pedestal removal, peak detection and
alignment. Noise-level spectra were estimated by finding the standard
deviation of the noise in the down-sampled spectra and adjusting
for the expected effect of filtering. Poisson dependence on baseline
amplitude was included to account for the observed dark current
amplification for early TOF. Integrated down-sampled signal intensities
were compared to exclude the influence of the originally different peak
widths. Implementation details and Matlab toolbox for signal processing
are available from matlabcentral/fileexchange/24469. Metrics for 9 m/z
peaks common to each of the three preparations included: measured
ion intensity, estimated noise, SNR, normalized intensity, normalized SNR
and %CV.
Figure 1 shows the mean raw spectra for each of the three preparations.
The top spectrum (SA spotted with the TL method on ground steel) proved
to be of highest quality based on SNR and reproducibility. Compared with
CHCA on Anchorchip, SA on steel produced 3.5× greater average signal
intensity and 10× greater average SNR (based on the average values for
all peaks and replicates for each sample preparation); whereas TL methods
on steel produced similar ion signals for both CHCA and SA. Noise was
greatly reduced with SA (1/3.5) giving an overall 3× increase in SNR for SA
over CHCA on steel. Comparing individual ion signals in Fig. 1 shows that
five of the nine ions have higher signals for CHCA on steel than for SA on
steel. However, only two of these ions (ubiquitin 3+ and 2+) have higher
SNR (with only 1.5× increase).
In the literature, the utilization of TL preps have focused generally
on increasing signal and reproducibility of peptides (m/z <4000) using
CHCA[21,22] or higher mass proteins (m/z >10 000) using SA.[23,24] However,
our interest is in the middle range – m/z 3000–20 000 – where LMW serum
protein peaks are commonly found. As Fig. 1 demonstrates, we determined
SA is a better matrix over CHCA in our modified TL method, due to the
reduced noise, higher SNR and resolution that SA offers in the 3–20 kDa
range.
Coefficients of variation (%CV) were calculated for experimental
replicates for each m/z peak based on normalized intensity and normalized
SNR. Table 1 presents the %CV for each peak and for each surface
preparation. The average %CVs for a given preparation are shown
at the bottom of the table. Reproducibility was comparable whether
Figure 2. Raw MALDI-TOF spectra of processed QC serum: (a) C3 magnetic bead fractionation, (b) 50K ultrafiltration + C3 purification and (c) 2% TFA
denaturation + 50K ultrafiltration + C3 purification.
wileyonlinelibrary.com/journal/jms Copyright c© 2010 John Wiley & Sons, Ltd. J. Mass. Spectrom. 2011, 46, 85–89
8
7
JMS Letter
Table 1. %CVs for PS1 ions (ten replicate average) for the studied MALDI preparations
Matrix/surface
Peak CHCA on anchor dried droplet CHCA on steel thin layer SA on steel thin layer
m/z (Da) Species Intensity SNR Intensity SNR Intensity SNR
2 855 Ub+3 17.0 16.4 7.8 6.5 17.3 18.5
2 867 In+2 16.3 16.9 9.9 11.7 13.4 11.4
4 283 Ub+2 6.0 5.9 5.2 5.2 9.1 9.7
5 734 In+1 25.3 25.6 7.7 8.2 7.8 7.0
6 181 Cyto+2 17.7 17.5 8.1 8.3 5.7 5.9
8 476 Myo+2 7.5 7.2 17.1 16.8 9.6 9.5
8 565 Ub+1 5.6 5.7 5.3 5.7 6.6 7.1
12 360 Cyto+1 9.0 8.3 7.5 7.5 3.7 3.8
16 952 Myo+1 8.0 7.1 19.1 18.0 12.3 12.0
Ave %CV 12.5 12.3 9.8 9.8 9.5 9.4
Table 2. Within and between samples %CVs based on replicate spotting of eight aliquots of QC serum processed by ultrafiltration (%CV values
calculated for 16 peaks normalized by SNR)
QC Aliquot
Peak m/z (Da)
A
(8 reps)
D
(9 reps)
G
(10 reps)
H
(10 reps)
J
(8 reps)
K
(10 reps)
M
(10 reps)
N
(9 reps)
Range %CV
(within sample)
Between sample
%CVa
2 371 24.1 13.9 15.3 23.5 10.3 16.1 16.6 13.7 10.3–24.1 23.2
2 596 9.2 13.7 7.3 11 12.5 13.1 13.1 12.7 7.3–13.7 21.8
2 924 19.8 10 8.7 12.3 16.8 21.2 32 38.2 8.7–38.2 47.3
3 182 17.7 11.6 9.1 7.8 19 14.7 25.5 18.5 7.8–25.5 42.6
3 252 28 8.1 6.5 6.8 19.5 13.4 19.2 14.9 6.5–28.0 45.6
3 338 17.3 12.6 8.8 10.3 13.6 12.6 11.6 10.5 8.8–17.3 19.3
3 938 17.2 9.7 9.1 4.8 7.2 5.4 5.8 4.4 4.4–17.2 20.3
4 075 35.5 8.2 5.7 6.1 5.6 4.6 5.2 8.3 4.6–35.5 21.7
4 194 14.2 8.3 4.2 4.8 2.9 3.9 6.6 6.9 2.9–14.2 18.4
4 766 17.6 11.1 11.1 5.1 10.2 13.9 12.5 11.7 5.1–17.6 17.7
4 942 25.2 7.3 9.6 8.5 13.9 10.8 18.1 10.5 7.3–25.2 15.9
5 311 29 5.4 3.8 5.4 4.5 5.4 5.4 5 3.8–29.0 13.4
5 874 30.6 9.1 7.4 4.8 3.5 2.8 4.4 7.4 2.8–30.6 14.5
6 036 21.7 8.7 8.3 5.4 4.9 5.7 5.1 7.4 4.9–21.7 12.9
6 628 22.5 12.8 10.1 14.8 12.1 17.7 14.7 23.6 10.1–23.6 26.4
9 218 35.1 25.4 11.2 5.9 13.8 5.8 18.5 8.8 5.8–35.1 42.4
Within sample ave %CV 22.8 11 8.5 8.6 10.6 10.4 13.4 12.7 8.5–22.8 25.2
a based on 74 replicates
mean CV : 12.3% within sample
mean CV : 25.2% between samples
using normalized intensity or SNR. All preps gave good within-day
reproducibility; however, the TL prep with SA on steel was slightly
better (%CV = 9.5). Our previous studies for reproducibility of calibration
spectra[25] indicated that under carefully preserved instrumental settings,
the %CV does not exceed 10% in the course of several months. This
confirmed that the major contribution to the variability of MS signals
comes from the sample preparation step rather than the instrument or
time of the study.
Ultrafiltration
Human QC serum samples[26] were used with Millipore Amicon ultrafiltra-
tion devices to optimize MALDI profiling of the LMW serum fraction.[27]
Devices were used according to the manufacturer’s recommendations.
Twenty-three comparisons were made depending on: (1) MWCO: 3, 10, 30,
50 and 100 K, (2) collecting filtrate or retentate, (3) filter size: 0.5 or 4 ml,
(4) double filter combinations, (5) denaturation and (5) MB-C3 purification.
A list of these combination preparations can be found in the Supporting
Information. All samples were MALDI spotted using the TL method with
SA on ground steel.
For the MWCO, we found that serum filtrate from the 50K filter gave
the best profile in the 3–20 kDa range. This was enhanced by pre-filtration
protein denaturation with 2% TFA and post-filtration C3 magnetic bead
desalting. Other filtrations that gave complimentary profiles (but less
overall coverage in the 3–20 kDa range) included the 10K retentate and
combination 50K filtrate followed by 3K retentate (data not shown). The
filter size did not matter unless double filtrations were performed (0.5 ml
filter for the second filtration).
Figure 2 shows MALDI spectra of processed serum. Figure 2(a) is a
typical profile of C3 magnetic bead processed QC serum. Figure 2(b) is 50K
filtered QC serum followed by C3 bead cleanup. In comparison, noise is
greatly reduced for the filtered sample which enhanced peaks in the m/z
2000–6000 range. Adding upfront 2% TFA denaturation (Fig. 2(c)), noise is
further reduced with enhanced peaks in the m/z 7000–10 000 range.
J. Mass. Spectrom. 2011, 46, 85–89 Copyright c© 2010 John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jms
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The reproducibility of the two-step serum preparation was determined
based on variation in peak intensities and normalized SNR. The systematic
reproducibility study was performed only for the best preparation method
(Fig. 2(c)), since other methods did not provide the desired signal gain
over the full LMW range. Eight separate aliquots of QC serum (eight
biological replicates) underwent 50 kDa centrifugal ultrafiltration and C3
magnetic bead purification. Prepared aliquots were spotted 10 times (10
experimental replicates) on a MALDI target. Raw QC spectra were processed
using the same procedures (with slightly different parameters) as the PS1
spectra. Sixteen m/z peaks were selected for comparison. From the data,
we found that intensity CVs were not correlated to the m/z value or mean
intensity value of a peak. In other words, the variation of a peak’s intensity
is independent of the absolute value of m/z and intensity. This has been
observed previously in MALDI profiling studies.[16,28]
Table 2 presents %CV values for each peak in each aliquot based on
normalized SNR. The ranges for %CV for each peak across all aliquots
are given in the second column from the right. The column to the far
right contains between sample %CV values calculated using data from all
replicates, both experimental and biological (74 replicates). The average
within and between sample %CVs are summarized at the bottom of the
table. No single aliquot yielded the highest or lowest %CV for all peaks.
There was no relationship found between %CV and average intensity,
noise or SNR.
The average CV per experimental replicate ranged from 8 to 23%, with
a mean CV of 12% within samples. The mean CV between samples ranged
between 13 and 47%, with an average of 25%. While this sample-to-sample
reproducibility of 25% is not very noteworthy, it is within the range of CVs
regularly observed in serum MS profiling assays.[16,18,28,29] Of greater note
is that the additional sample processing steps – ultrafiltration, C3 – did
not significantly impact within sample reproducibility (12% for serum with
ultrafiltration/C3 compares well with 9% for PS1 without). Additionally, the
MALDI profiling is greatly enhanced in the LMW serum protein range.
In conclusion, currently there is debate as to the diagnostic utility
of LMW protein/peptide signatures since all the potential markers to
date correspond to proteolytic fragments of the most abundant plasma
proteins.[8,30] However, our ultrafiltration/MALDI method extensively
improves peptide/protein peak intensities and reproducibility in the
3–20 kDa range. Our preliminary results (data not shown) comparing
prostate cancer to normal serum samples indicate significant peak
differences in the LMW range. For future work, we plan to conduct
a larger LMW serum clinical profiling study of prostate cancer-related
samples using our denaturing ultrafiltration technique.
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